Steven Kaufman talks with ONdrugDelivery about the world of autoinjectors, looking at the current status quo in the industry, using Portal Instruments’ PRIME Nexus™ smart reusable electromechanical autoinjector as a lens to bring into focus how things have changed and where they might be going.
Steven Kaufman discusses the rapidly evolving world of drug delivery and the future of self-injection.
In this exclusive interview, Kaufman highlights the tipping point the industry is facing, driven by a crucial need for sustainability and cost-effectiveness in an era of billions of disposable devices. He sheds light on the next generation of solutions, focusing on the rise of smart, reusable, electromechanical autoinjectors.
Using Portal Instruments' PRIME Nexus™ device as a key example, Kaufman explains how innovative platforms are designed to handle challenges like high-viscosity formulations and varying fill volumes, all while significantly reducing environmental impact. Learn how devices that prioritize the entire value chain, from manufacturing to elegant design and digital health integration, are setting the new standard for improved patient adherence and successful combination product programs.
The full article can be found in ONdrugDelivery.
Portal Instrument's CEO, Dr. Patrick Anquetil, shares insights on reducing healthcare waste through reusable autoinjectors in a compelling OnDrug Delivery interview, "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors."
Today Portal Instruments announced the signing of a multi-million-dollar development agreement with a leading biotech company to advance its large-volume, reusable autoinjector, PRIME NEXUS™, toward clinical readiness in Q1 2027.
October 29, 2020 - Patrick Anquetil, CEO Portal Instruments, demos Portal’s needle-free injector, shares his perspective on being an entrepreneur and discusses Portal’s opportunities during COVID with Radio Entrepreneurs host Jeffrey Davis.
Please fill out the details below and we will get back to you shortly.